History
A list of downloadable documents created during development.
Background information
-
-
-
-
Appendix A - provisional matrix of stakeholders (PDF 103 KB)
-
Appendix B - addendum to the review considerations for TA158 and TA168 (PDF 146 KB)
-
Appendix C - consultee and commentator comments on TA168 proposal (PDF 102 KB)
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 79 KB)
-
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 280 KB)
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination
-
-
-
-
Consultee and commentator comments on the ACD
-
-
-
Professional and patient groups: British Thoracic Society (PDF 15 KB)
-
-
Professional and patient groups: General Practice Airways Group (PDF 41 KB)
-
Professional and patient groups: Health Protection Agency (PDF 23 KB)
-
Professional and patient groups: Royal College of Paediatrics and Child Health (PDF 62 KB)
-
Professional and patient groups: Royal College of Physicians (PDF 11 KB)
-
Professional and patient groups: Royal College of Nursing (PDF 20 KB)
-
-
-
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: appraisal consultation
-
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: appraisal consultation
-
-
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: evaluation report
-
-
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: assessment report (PDF 1.31 MB)
-
Consultee and commentator comments on the assessment report
-
Consultee and commentator comments on the assessment report: British Thoracic Society (PDF 18 KB)
-
Consultee and commentator comments on the assessment report: Diabetes UK (PDF 45 KB)
-
Consultee and commentator comments on the assessment report: GlaxoSmithKline (PDF 27 KB)
-
Consultee and commentator comments on the assessment report: Roche (PDF 98 KB)
-
Consultee and commentator comments on the assessment report: Royal College of Nursing (PDF 13 KB)
-
Consultee and commentator comments on the assessment report: Royal College of Physicians (PDF 14 KB)
-
Non-manufacturer submissions
-
Non-manufacturer submissions: British Thoracic Society (PDF 55 KB)
-
-
Non-manufacturer submissions: Health Protection Agency (PDF 76 KB)
-
Non-manufacturer submissions: Royal College of Nursing (PDF 14 KB)
-
Non-manufacturer submissions: Royal College of Physicians (PDF 42 KB)
-
Manufacturer submissions (executive summary only)
-
Manufacturer submissions (executive summary only): Roche (PDF 556 KB)
-
Manufacturer submissions (executive summary only): GlaxoSmithKline (PDF 159 KB)
-
Manufacturer submissions (executive summary only): Alliance Pharmaceuticals (PDF 14 KB)
-
Expert written personal statements
-
-
-